Competition authority has given its approval of the merger of Oriola’s and Euroapotheca’s Swedish pharmacy operations

Oriola Corporation Stock Exchange Release 30 June 2022 at 7.00 p.m.

Competition authority has given its approval of the merger of Oriola’s and Euroapotheca’s Swedish pharmacy operations

The Swedish Competition Authority (Konkurrensverket) has given its approval of the planned merger in which Oriola Corporation and the Euroapotheca group combine their respective pharmacy businesses in Sweden, Oriola’s Kronans Apotek and Euroapotheca’s Apoteksgruppen into a new company. Preparations for the completion of the merger are ongoing and the completion of the merger is expected to take place early October 2022.

Oriola announced on 9 February 2022, that it has signed a framework merger agreement for combining its pharmacy business in Sweden with the respective Swedish pharmacy business of Euroapotheca. The new company will have over 470 pharmacies and full online pharmacy operations, over 2,300 full-time employees and an illustrative combined revenue of EUR 1,140 million as of 2020 in Sweden. The new company is expected to be the third largest player in the Swedish pharmacy market by revenue, with an estimated combined market share of 25 percent.

Oriola Corporation
Katarina Gabrielson
CEO

Further information:

Katarina Gabrielson
CEO
tel. +46 72 234 8809
email: katarina.gabrielson@oriola.com

Tuula Lehto
VP, Communications and Sustainability
tel. +356 40 5885 343
email: Tuula.lehto@oriola.com

Distribution:
Nasdaq Helsinki Ltd.
Key media

Released by:
Oriola Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo, Finland
www.oriola.com